FDA clears Pyxis Oncology INDs for PYX-201 ADC and PYX-106 immunotherapy

Pyxis Oncology, Inc.

FDA cleared IND for PYX-201, an ADC targeting tumor microenvironment for breast, head/neck, lung, thyroid cancers.
FDA cleared IND for PYX-106, an immunotherapy targeting Siglec-15 for bladder, cholangiocarcinoma, colorectal, kidney cancers.
Phase 1 trials planned to start in early 2023; cash runway extended into first half 2025.
Pyxis Oncology transitions to clinical-stage company with veteran leadership team.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.